Cellular pathways of joint destruction

Current Opinion in Rheumatology

Volumn 9, Issue 3, 1997, Pages 213-220

  Müller Ladner, Ulf ^a   Gay, Renate E ^b   Gay, Steffen ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CARTILAGE; CARTILAGE DEGENERATION; CELL ADHESION; CELL CYCLE; CELL INTERACTION; FIBROBLAST; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; JOINT DESTRUCTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; TRANSCRIPTION INITIATION;

ARTHRITIS, RHEUMATOID; CELL CYCLE; HUMANS; JOINTS; RECEPTORS, CELL SURFACE; TRANSCRIPTION, GENETIC;

EID: 0031011528     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199705000-00007     Document Type: Review

References (77)

1. Gay S, Gay RE, Koopman WJ: Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993, 52:S39-S47.
2. Firestein GS: Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996, 39:1781-1790. Highlights the role of fibroblastlike synoviocytes in the progressive destruction of joints in RA.
3. Gay S, Kalden JR: Retroviruses and autoimmune rheumatic diseases. Clin Exp Immunol 1994, 98:1-5.
4. Müller-Ladner U, Kriegsmann J, Gay RE, Gay S: A rapid new double-labeling technique for tissue specimens: immunogold-silver staining for in situ hybridization combined with alkaline-phosphatase anti alkaline phosphatase (APAAP) immunohistochemistry for antigens. Histochem J 1996, 28:133-140. The authors present a rapid method for double labeling of mRNA and cellular or matrix antigens on RA synovial frozen sections.
5. Kriegsmann J, Keyszer GM, Geiler T, Bräuer R, Gay RE, Gay S: Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid arthritis synovium demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 1995, 72:209-213.
6. Tak PP, Thurkow EW, Daha MR, Kluin PM, Smeets TJ, Meinders AE, Breedveld FC: Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunpathol 1995, 77:236-242.
7. Hayashi T, Abe E, Jasin HE: Fibronectin synthesis in superficial and deep layers of normal articular cartilage. Arthritis Rheum 1996, 39:567-573.
8. Hino K, Maeda T, Sekiguchi K, Shiozawa K, Hirano H, Sakashita E, Shiozawa S: Adherence of synovial cells on EDA-containing fibronectin. Arthritis Rheum 1996, 39:1685-1692.
9. Kitani A, Nakashima N, Matsuda T, Xu B, Yu S, Nakamura T, Matsuyama T: T cells bound by vascular cell adhesion molecule-1/CD106 in synovial fluid in rheumatoid arthritis: inhibitory role of soluble vascular cell adhesion molecule-1 in T cell activation. J Immunol 1996, 156:2300-2308.
10. Tessier PA, Cattaruzzi P, McColl SR: Inhibition of lymphocyte adhesion to cytokine-activated synovial fibroblasts by glucocorticoids involves the attenuation of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 gene expression. Arthritis Rheum 1996, 39:226-234. Provides data explaining some of the beneficial effects of glucocorticoids occurring by downregulation of adhesion molecules on RA synovial fibroblasts.
11. To SST, Newman PM, Hyland VJ, Robinson BG, Schrieber L: Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. Arthritis Rheum 1996, 39:467-477.
12. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Maini RN: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081. Inhibition of TNF has been shown to reduce inflammation in several clinical trials. The authors demonstrate that one of the effects of TNF inhibition may be downregulation of adhesion molecules.
13. Matthias LJ, Gotis-Graham I, Underwood PA, McNeil HP, Hogg PJ: Identification of monoclonal antibodies that recognize different disulfide bonded forms of thrombospondin 1. Biochim Biophys Acta 1996, 1296:138-144.
14. Trollmo C, Nilsson IM, Sollerman C, Tarkowski A: Expression of the mucosal lymphocyte integrin αEβ7 and its ligand E-cadherin in the synovium of patients with rheumatoid arthritis. Scand J Immunol 1996, 44:293-298.
15. Riikonen T, Westermarck J, Koivisto L, Broberg A, Kähäri VM, Heino J: Integrln α2β1 is a positive regulator of collagenase (MMP-1) and collagen α1(1) gene expression. J Biol Chem 1995, 270:13548-13352.
16. Pirilä L, Heino J: Altered Integrin expression in rheumatoid synovial lining type B cells: in vitro cytokine regulation of α1β1, α6β1, αvβ5 integrins. J Rheumatol 1996, 23:1691-1698.
17. 1-receptors. Virchows Arch 1995, 427:437-444.
18. Koch AE, Kunkel SL, Shah MR, Fu R, Mazakaris DD, Haines GK, Burdick MD, Pope RM, Stricter RM: Macrophage inflammatory protein-1β: a C-C chemokine in osteoarthritis. Clin Immunol Immunpathol 1995, 77:307-314.
19. Koch AE, Kunkel SL, Shah MR, Hosaka S, Halloran MM, Haines GK, Burdick MD, Pope RM, Stricter RM: Growth-related gene product-α: a chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995, 155:3660-3666.
20. Kunkel SL, Lukacs N, Kasama T, Strieter RM: The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996, 59:6-12. This outstanding review describes precisely our current knowledge of chemokines in arthritic diseases, including a distinct emphasis on the role of interteukin-10.
21. Müller-Ladner U, Franklin BN, Roberts CR, Gay RE, Robbins PD, Evans CH, Gay RE: Gene transfer of interleukin-10 into human synovial fibroblasts and implantation into the SCID mouse. Arthritis Rheum 1996, 39:S160.
22. Mori N, Shirakawa F, Abe M, Kamo Y, Koyama Y, Murakami S, Shimizu H, Yamamoto K, Oda S, Eto S: Human T-cell leukemia virus type I tax transactivates the interleukin-6 gene in human rheumatoid synovial cells. J Rheumatol 1995, 22:2049-2054. Demonstration of a potentially important pathway in RA, the upregulation of proinflammatory cytokines in RA synovial fibroblasts by retroviral transformation.
23. Müller-Ladner U, Kriegsmann J, Gay RE, Gay S: Oncogenes in rheumatoid arthritis. Rheum Dis Clin North Am 1995, 21:675-690.
24. Roivainen A, Söderström K-O, Pirilä L, Arc H, Kortekangas P, Merilahti-Palo R, Yli-Jama T, Toivanen A, Toivanen P: Oncoprotein expression in human synovial tissue: an immunohistochemical study of different types of arthritis. Br J Rheumatol 1996, 35:933-942.
25. Wong WM, Howell WM, Coy SD, Cawley MID, Smith JL: Interleukin-2 is found in the synovium of psoriatic arthritis and spondylarthritis, not in rheumatoid arthritis. Scand J Rheumatol 1996, 25:239-245.
26. Handel ML, McMorrow LB, Gravallese EM: Nuclear factor kappa B in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995, 38:1762-1770. Nice study showing the presence of both subunits of NFκB in RA synovium, especially in synovial lining macrophages and endothelial cells.
27. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morns CJ, Blake DR, Kaltschmidt C, Baeuerle PA: Activation of the transcription factor nuclear factor KB in human inflamed synovial tissue. Arthritis Rheum 1996, 39:583-591. Presents data on the association of flares of arthritis with a predominance of NFicB in endothelium of RA synovial microvasculature.
28. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H: High DNA-binding activity of transcription factor NFκB in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995, 37:827-832. Interesting study showing that the binding activity of NFκB is enhanced in RA synovium as compared with osteoarthritis synovium.
29. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K: Activation of transcription factor NFicB in human synovial cells in response to tumor necrosis factor-α. Arthritis Rheum 1996, 39:197-203. Nuclear factor κB is one of the key molecules in regulation of gene transcription. The authors provide data on the regulation of NFκB by proinflammatory cytokines.
30. Boumpas DT: A novel action of glucocorticoids: NFκB inhibition. Br J Rheumatol 1996, 35:709-710. A succinct, well-written review on our current knowledge of the effects of glucocorticoids on NFκB regulation.
31. Wang F, Sengupta, Zhong Z, Ivashkiv LB: Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 1995, 182:1825-1831.
32. Müller-Ladner U, Schindler U, Gay RE, McKnight S, Gay S: Expression of interleukin-4 STAT (IL-4 STAT) mRNA, STAT6 and JAK protein in synovium of patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:S304.
33. Migita K, Eguchi K, Aoyagi T, Tsukada T, Tsuboi M, Kawabe Y, Nagataki S: The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblasts. Clin Exp Immunol 1996, 104:86-91.
34. Vincenti PV, Coon CI, White LA, Barchowsky A, Brinckerhoff CE: src-related tyrosine kinases regulate transcriptional activation of the interstitial collagenase gene, MMP-1, in interleukin-1-stimulated synovial fibroblasts. Arthritis Rheum 1996, 39:574-582. Presents detailed information on a complete pathway in synovial fibroblasts, starting with cytokine stimulation, followed by upregulation of protooncogenes and tyrosine kinases, and resulting in the production of a matrix-degrading protease.
35. Schwarting A, Schlaak J, Lotz J, Pfers I, Meyer zum Büschenfelde K-H, Mayet W-J: Endothelin-1 modulates the expression of adhesion molecules on fibroblast-like synovial cells (FLS). Scand J Rheumatol 1996, 25:246-256.
36. Mountz JD, Wu J, Cheng J, Zhou T: Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994, 37:1415-1420.
37. Matsumoto S, Müller-Ladner U, Gay RE, Nishioka K, Gay S: Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J Rheumatol 1996, 23:1345-1352. First report on the characteristic multistep pattern of apoptosis of RA synovial fibroblasts.
38. Sugiyama M, Tsukazaki T, Yonekura A, Matsuzaki S, Yamashita S, Iwasaki K: Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1996, 55:442-449.
39. Isomäki P, Söderström K-O, Punnonen J, Roivainen A, Luukainen R, Merilathi-Palo R, Nikkari S, Lassila O, Toivanen P: Expression of bcl-2 in rheumatoid arthritis. Br J Rheumatol 1996, 35:611-619.
40. Tsuboi M, Eguchi K, Kawakami A, Matsuoka N, Kawabe Y, Aoyagi T, Maeda K, Nagataki S: Fas antigen expression on synovial cells was down-regulated by interleukin-1β. Biochem Biophys Res Commun 1996, 218:280-285. Interesting report of a hitherto unknown effect of interleukin-1-the inhibition of Fas antigen expression on synovial cells-that may support a prolonged proliferation of these cells.
41. Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Kawabe Y, Aoyagi T, Nagataki S: Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor-β. Arthritis Rheum 1996, 39:1267-1276.
42. Fujisawa K, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T, Nishioka K: Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I tax transgenic mice. J Clin Invest 1996, 98:271-278. Convincing presentation of the therapeutic potential of anti-Fas antibodies in an animal model with pathophysiologic aspects similar to those of human RA.
43. Hoa TTM, Hasunuma T, Aono H, Masuko K, Kobata T, Yamamoto K, Sumida T, Nishioka K: Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. J Rheumatol 1996, 23:1332-1337.
44. Shimozato O, Watanabe N, Goto M, Kobayashi Y: Cytokine production by SV40-transformed adherent synovial cells from rheumatoid arthritis patients. Cytokine 1996, 8:99-105.
45. Motokawa S, Hasunuma T, Tajima K, Krieg AM, Ito S, Iwasaki K, Nishioka K: High prevalence of arthropathy in HTLV-I carriers on a Japanese island. Ann Rheum Dis 1996, 55:193-195.
46. Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S: High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39:463-466.
47. Starkebaum G, Shasteen NM, Fleming-Jones RM, Loughran TP Jr, Mannik M: Sera of patients with rheumatoid arthritis contain antibodies to recombinant human T lymphotropic virus type I/II envelope glycoprotein p21. Clin Immunol Immunopathol 1996, 79:182-188.
48. Albani S, Carson DA: A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol Today 1996, 17:466-470. Interesting review addressing the role of molecular mimicry in the development of RA.
49. Ermis A, Henn W, Remberger K, Hopf C, Hopf T, Zang KD: Proliferation enhancement by spontaneous multiplication of chromosome 7 in rheumatic synovial cells in vitro. Hum Genet 1995, 96:651-654.
50. Ronday HK, Smits HH, Van Muijen GN, Pruszczynski MS, Dolhain RJ, Van Langelaan EI, Breedveld FC, Verheijen JH: Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996, 35:416-423.
51. Grabowski PS, Macpherson H, Ralston SH: Nitric oxide production in cells derived from the human joint. Br J Rheumatol 1996, 35:207-212.
52. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N: Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995, 96:2357-2363.
53. Frenkel SR, Clancy RM, Ricci JL, Di Cesare PE, Rediske JJ, Abramson SB: Effects of nitric oxide on chondrocyte migration, adhesion, and cytoskeletal assembly. Arthritis Rheum 1996, 39:1905-1912.
54. Maeda S, Sawai T, Uziki M, Takahashi Y, Omoto H, Seki M, Sakurai M: Determination of interstitial collagenasa (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54:970-975.
55. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ: Expression of matix metalloproteinase 9 (96-kD gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996, 39:1576-1587.
56. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kow RR, Arbeit LA: Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunpathol 1996, 78:161-171.
57. Nemoto O, Yamada H, Mukaida M, Shimmei M: Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum 1996, 39:560-566.
58. Martel-Pelletier J, Pelletier J-P: Wanted: the collagenase responsible for the destruction of the collagen network in human cartilage. Br J Rheumatol 1996, 35:818-820. A detailed review addressing the current problems in identifying the molecules responsible for collagen degradation in human cartilage.
59. Müller-Ladner U: Molecular and cellular interactions in rheumatoid synovium. Curr Opin Rheumatol 1996, 8:210-220.
60. Kang RY, Freire-Moar J, Sigal E, Chu G-Q: Expression of cyclooxygenase-2 in humans and an animal model of rheumatoid arthritis. Br J Rheumatol 1996, 35:711-718.
61. Franz JK, Hummel KM, Aicher WK, Petrow PK, Gay RE, Gay S: In-situ detection of cyclooxygenase (COX) 1 and 2 mRNA in rheumatoid arthritis (RA) and osteoarthritis (OA) synovium. Arthritis Rheum 1996, 39:3197.
62. 2 from human articular chondrocytes. J Rheumatol 1995, 22:2114-2119.
63. 2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II, but not of cyclo-oxygenase I. Ann Rheum Dis 1996, 55:375-382. Inhibition of cyclooxygenase-2 is one of the novel therapeutic concepts in RA. The authors provide data on the biologic effects of interleukin-4 on cyclooxygenase expression.
64. Nickerson-Nutter CL, Medvedeff E: The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum 1996, 39:515-521.
65. Sugiyama E, Kuroda A, Taki H, Ikemoto M, Hori T, Yamashita N, Maruyama M, Kobayashi M: Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995, 22:2020-2026. Description of a very interesting additive mechanism of two inhibitory cytokines on the production of proinflammatory cytokines.
66. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J: Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996, 39:386-395.
67. Van Roon JA, Van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW: Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996, 39:829-835.
68. Lundberg C, Åsberg I, Ionescu M, Reiner A, Smedegárd G, Poole RA: Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: studies of synovial fluid and articular cartilage. Ann Rheum Dis 1996, 55:525-534.
69. Nakamura S, Kamihagi K, Satakeda H, Katayama M, Pan H, Okamoto H, Noshiro M, Takahashi K, Yoshihara Y, Shimmei M, Okada Y, Kato Y: Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage: increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum 1996, 39:539-551.
70. McCurdy L, Chatham WW, Blackburn WD Jr: Rheumatoid synovial fibroblast adhesion to human articular cartilage: enhancement by neutrophil proteases. Arthritis Rheum 1995, 38:1694-1700.
71. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier J-P: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544. One of the key experiments addressing the inhibitory effects of interleukin-1 receptor antagonist on the expression of matrix-degrading enzymes.
72. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS Jr, Haskill JS, Schwab JH: Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A 1996, 93:402-406. First report of the suppression of experimental arthritis by interleukin-1 receptor antagonist gene transfer into rat synovial fibroblasts.
73. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH: Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996, 156:3558-3562. In addition to the results of Makarov et al. (Proc Natl Acad Sci U S A 1996, 93:402-406), the authors demonstrate for the first time a considerable reduction of cartilage breakdown following retrovirus-based gene transfer of interleukin-1 receptor antagonist into synovial fibroblasts.
74. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH: Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996, 156:3558-3562. In addition to the results of Makarov et al. (Proc Natl Acad Sci U S A 1996, 93:402-406), the authors demonstrate for the first time a considerable reduction of cartilage breakdown following retrovirus-based gene transfer of interleukin-1 receptor antagonist into synovial fibroblasts.
75. Müller-Ladner U, Roberts CR, Franklin BN, Gay RE, Robbins PD, Evans CH, Gay S: Human IL-1Ra gene transfer into human synovial fibroblasts is Chondroprotective. J Immunol 1997, in press.
76. Häuselmann HJ, Flechtenmacher J, Michal L, Thonar EJ-MA, Shinmei M, Kuettner KE, Aydelotte MB: The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum 1996, 39:478-488. A most interesting experiment showing the different susceptibility of articular chondrocytes to interleukin-1-induced cartilage degradation dependent on their spatial relation to the articular surface.
77. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially antiarthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996, 7:1261-1280. Presents the details of the first clinical gene therapy trial for RA in humans. May be one of the cornerstones for a new era in novel therapeutic strategies.